A newly published journal article examined current practices of HTCs for screening and assessing bone health in people with hemophilia and von Willebrand disease.

We are celebrating this National Social Work Month of March by highlighting resources to help support our hemophilia treatment center social workers and to recognize the critical work they do on behalf of people with bleeding disorders and their families.

Takeda Pharmaceuticals announced today it will globally discontinue two of its hemophilia treatments: HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)].

Included in this edition are educational booklets, articles, and video recordings of substantive presentations on topics related to rare factor deficiencies and inherited platelet disorders.

On Jan 27, 2025, Bill Robie testified before North Dakota lawmakers in support of HB 1216, aiming to lower out-of-pocket drug costs for bleeding disorders.

NBDF reaffirms its dedication to all in the bleeding disorders community, prioritizing health equity, diversity, and inclusion.

This activity is intended for learners to enhance their ability to recognize the key differences in gene therapies for hemophilia A compared with hemophilia B, and to leverage evolving data about gene therapies for hemophilia to better care for patients.

The FDA’s Fast Track designation is meant to facilitate the development and expedite the review of drugs that treat a broad range of serious conditions and address an unmet medical need.

The National Bleeding Disorders Foundation (NBDF) is pleased to announce the appointment of three new distinguished members to its Board of Directors, effective January 1, 2025.